U.S. Patient Access
Gilead Patient Assistance Programs
Our U.S. patient assistance programs help make Gilead therapies accessible for uninsured individuals and those who need financial assistance. These programs include:
Gilead also supports programs for those unable to afford the co-payments associated with health insurance programs.
U.S. Advancing Access®
The ADVANCING ACCESS® patient assistance program is committed to helping patients afford their Gilead medication, including:
- Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide)
- Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate)
- Descovy® (emtricitabine/tenofovir alafenamide)
- Emtriva® (emtricitabine)
- Genvoya® (elvitegravir/cobicistat/emtricitabine/
- Odefsey® (emtricitabine/rilpivirine/tenofovir alafenamide)
- Stribild® (elvitegravir/cobicistat/emtricitabine/
tenofovir disoproxil fumarate)
- Truvada® (emtricitabine/tenofovir disoproxil fumarate)
- Tybost® (cobicistat)
- Vemlidy® (tenofovir alafenamide)
- Viread® (tenofovir disoproxil fumarate)
Advancing Access provides assistance to patients who are uninsured, underinsured or who need financial assistance to pay for the medicine. The program offerings for patients include:
- Access to call center associates who can help patients and their providers with insurance-related questions, including providing information regarding coverage options.
- Provides co-pay assistance for eligible patients who need assistance paying for out-of-pocket medication costs. This program is not valid for patients enrolled in government healthcare prescription drug programs, such as Medicare Part D and Medicaid. Patients in the coverage gap known as the "donut hole" also are not eligible.
- The Advancing Access patient assistance program provides Gilead medications at no charge for eligible patients with no other insurance options.
Information about how to apply for any of these forms of assistance can be found at www.GileadAdvancingAccess.com or by calling
Truvada for PrEP Medication Assistance Program
Gilead is committed to ensuring that individuals at risk of HIV have access to Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) tablets. We support comprehensive payer coverage and maintain the Gilead Advancing Access® program for qualified individuals in the United States who cannot afford their medications. This includes our Truvada for PrEP Medication Assistance Program (MAP), which assists eligible HIV-negative adults in the United States who require assistance paying for Truvada for PrEP (pre-exposure prophylaxis).
To ensure we are addressing the affordability challenges, Gilead regularly evaluates its support programs for individuals at risk of HIV who are either considering or taking Truvada for PrEP.
We are pleased to announce an enhancement to the Gilead MAP program:
- Effective July 1, 2018, individuals who qualify for the MAP will be eligible for 12 months rather than six months. This change will make it easier for individuals to enroll and remain in the program.
To find out if you are eligible for this medication assistance program, call +1 855 330 5479+1 855 330 5479, Monday through Friday between 9:00 a.m. and 8:00 p.m. (Eastern), or visit www.gileadadvancingaccess.com to learn more about the program, including the financial support that may be available for Truvada for PrEP.
Letairis Education and Access Program
The Letairis Education and Access Program (LEAP) helps patients navigate the reimbursement process, and assist those without adequate financial resources identify alternate means of support for access to Letairis (ambrisentan).
To find out if you are eligible for this patient assistance program, call +1 866 664 5327 +1 866 664 5327 Monday through Friday between 9:00 a.m. and 8:00 p.m. (Eastern).
Cayston Access Program®
The Cayston Access Program® coordinating center (or patient assistance program) assists eligible patients with cystic fibrosis and members of their care team with insurance verification, referral to participating specialty pharmacies, claims support and co-pay assistance. As part of this program, Gilead also provides assistance to qualified patients in the United States who cannot afford to pay for Cayston® (aztreonam for inhalation solution).For information about the Cayston Access Program®, call
The Support Path™ patient assistance program assists eligible Hepatitis C patients in the United States access Sovaldi® (sofosbuvir), Epclusa® (sofosbuvir/velpatasvir) or Harvoni® (ledipasvir/sofosbuvir). The program offerings include:
- A call center staffed with associates trained to help patients and their providers with insurance-related information.
- Access education and support, such as a 24/7 nursing support service line.
- Co-pay Coupon Programs, which provide co-pay assistance for eligible patients with private insurance who need assistance paying for their out-of-pocket medication costs. Most eligible patients will pay no more than $5 per co-pay (restrictions apply). Not valid for patients enrolled in government healthcare prescription drug programs, such as Medicare Part D and Medicaid. Patients in the coverage gap known as the "donut hole" also are not eligible.
- The Support Path™ Patient Assistance Program will provide Sovaldi®, Harvoni®, or Epclusa® at no charge for eligible and qualified uninsured patients.
To learn more about Support Path™, please call
Gilead is committed to ensuring that patients with CLL, FL and SLL can access Zydelig® and has launched Zydelig® AccessConnect™ to provide assistance to patients who are uninsured, underinsured or who need financial assistance to pay for the medicine. The program resources include:
- Access to case specialists to help patients and their providers with insurance-related questions, including identifying coverage options.
- The Zydelig® co-pay coupon program, which provides co-pay assistance for eligible patients with private insurance who need assistance paying for out-of-pocket medication costs. Most patients will pay no more than $5 per monthly co-pay.
- Eligible patients who have been prescribed Zydelig® for an FDA-approved indication and who are experiencing insurance coverage delays greater than five business days may receive a 30-day supply of Zydelig® while coverage is established.
- Patients enrolled into Zydelig® AccessConnect™ may be referred to a specialty pharmacy based on the policies of their individual health plan.
- The AccessConnect™ patient assistance program will provide Zydelig® at no charge for eligible patients that qualify for assistance.
Information about how to apply for any of these forms of assistance, and more information on authorized distributors and specialty pharmacies can be found at www.zydeligaccessconnect.com or by calling
Kite Konnect™ is committed to helping patients and healthcare teams throughout YESCARTA® (axicabtagene ciloleucel) treatment, including:
- Patient enrollment
- Reimbursement support
- Logistics support
- Ongoing commitment